Targeting Nerve Growth Factor (NGF) for Pain Management: What Does the Future Hold for NGF Antagonists?
- 1.8k Downloads
It is unanimously accepted that there is an unmet need for pain medications that are both effective and safe. Unfortunately, no really novel analgesics have been approved over the past three decades. In view of both experimental and clinical evidence of a major role for nerve growth factor (NGF) in the generation and maintenance of a wide range of pain states, drug discovery efforts focusing on the development of anti-NGF agents have aroused particular interest. Several humanized anti-NGF monoclonal antibodies (mAbs) have entered clinical trials as potential analgesics. In this respect, tanezumab is at an advanced stage of clinical development while fulranumab, fasinumab and ABT-110, previously known as PG110, are in early phases of clinical development. This Current Opinion article aims at describing the rationale for targeting NGF for pain, reviewing the analgesic efficacy and safety of anti-NGF agents based on data from fully published studies, conference abstracts, and the US Food and Drug Administration (FDA) website, and discussing the possible future of these agents in managing chronic pain. Anti-NGF mAbs produced significant pain relief and functional improvement in patients with osteoarthritis of the knee and/or hip. Conversely, studies in non-specific lower back pain generated mixed results; overall, this condition appeared to be less responsive to anti-NGF agents than osteoarthritis. Finally, there was no conclusive evidence of the effectiveness of anti-NGF mAbs in some types of chronic visceral or neuropathic pain. Furthermore, these studies raised safety concerns about anti-NGF mAbs. As a class, these drugs may cause or worsen peripheral neuropathies. But the most problematic issue—which prompted the FDA to place studies of these compounds on clinical hold in 2010—was rapid joint destruction leading to joint replacement surgery. The aetiologies of these side effects have been much debated and their pathophysiology is poorly understood. After an Arthritis Advisory Committee meeting held in March 2012, pharmaceutical companies negotiated with the FDA on the conditions for restarting clinical studies. Although the FDA lifted its clinical hold, there remain many unresolved issues about the long-term efficacy and safety of anti-NGF mAbs. While acknowledging that the future of these drugs is unforeseeable, it appears that they may not be the safe and effective painkillers that have been awaited for decades.
KeywordsLower Back Pain Nerve Growth Factor Neuropathic Pain Transient Receptor Potential Vanilloid Interstitial Cystitis
Acknowledgments and Conflicts of Interest
B. Bannwarth has received consulting fees from Janssen R&D, and honoraria from Pfizer. M. Kostine has no conflicts of interest. No sources of funding were used to support the writing of this manuscript.
- 14.Balanescu AR, Feist E, Wolfram G, et al. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis. 2013 (in press).Google Scholar
- 15.Yazici Y, Ekman EF, Greenberg HS, et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354) [abstract]. Arthritis Rheum. 2011;63(Suppl 10):S828.Google Scholar
- 16.Tive L, Dabezies EJ, Fountaine RJ, et al. Long-term safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis (NCT00994890) [abstract]. Arthritis Rheum. 2013;65(Suppl 10):S911–2.Google Scholar
- 19.Tiseo P, Kivitz AJ, Ervin JE, et al. REGN475/SAR164877, a nerve growth factor inhibitor, in osteoarthritis patients with moderate to severe knee pain [abstract]. Arthritis Rheum. 2010;62(Suppl 10):S710.Google Scholar
- 22.Sanga P, Karcher K, Wang K, et al. Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe chronic low back pain [abstract]. J Pain. 2011;12(Suppl 4):P53.Google Scholar
- 23.Food and Drug Administration Center for Drug Evaluation and Research. Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm286552.htm, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM301302.pdf (Accessed 28 Dec 2013).
- 28.Romano G, Wang H, Ritz J, et al. Analgesic efficacy of fulranumab in patients with neuropathic pain in a randomized, placebo-controlled, double blind study. 14th World Congress on Pain, Milano; 2012, abstract PT452. http://www.abstracts2view.com/iasp/view.php?nu=107827&type=abstract (Accessed 28 Dec 2013).
- 30.Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the Arthritis Advisory Committee Meeting; 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM307879.pdf (Accessed 15 Jan 2014).